



The Privilege of Proton Magnetic Resonance Spectroscopy in Evaluating Ovarian Tumors

Thesis

*Submitted for Partial Fulfillment of the Master
Degree in Radio diagnosis*

By

Noor Laith Salman

M.B, Ch.B

Supervised by

Prof. Abeer Abd-Almaqsoud Hafez

Professor of Radiodiagnosis

Faculty of Medicine – Ain Shams University

Dr. Merhan Ahmed Nasr

Lecturer of Radiodiagnosis

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Abeer Abd-Elmaqsoud Hafez**, Professor of Radiodiagnosis Faculty of Medicine – Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Merhan Ahmed Nassr**, Lecturer of Radiodiagnosis Faculty of Medicine – Ain Shams University, for her kind care, valuable instructions, and great assistance throughout this work.*

Noor Laith Salman





This work is dedicated to . . .

My beloved Father, to whom I owe everything I ever did in my life and will achieve.

My Mother for always being there for me and all the nights she stayed with me.

My Brother and *My Sister* for their support

My Husband for being the light of my life and God's gift to me, my backbone

Finally *My Lovely Kids Jana & Qamar*



List of Contents

Title	Page No.
List of Abbreviations	6
List of Tables	7
List of Figures	9
Introduction	1
Aim of the Work.....	15
Review of Literature	
▪ Anatomy of the Ovary	16
▪ Pathology of the Ovarian Tumors	26
▪ Pelvic MR Imaging Techniques	48
▪ MR Imaging Features of Ovarian tumors	67
Patients and Methods	92
Results	99
Case Presentation	125
Discussion	139
Summary	147
Conclusion.....	148
References	149
Arabic Summary	—

List of Abbreviations

Abb.	Full term
<i>Ala</i>	<i>Alanine</i>
<i>BOLD</i>	<i>Blood oxygen level-dependent</i>
<i>Cc</i>	<i>Choriocarcinoma</i>
<i>CHESS</i>	<i>Chemical-shift selective suppression</i>
<i>Cho</i>	<i>Choline</i>
<i>Cr</i>	<i>Creatine</i>
<i>CSI</i>	<i>Chemical shift imaging</i>
<i>DCE-MRI</i>	<i>Dynamic contrast-enhanced MRI</i>
<i>DWI</i>	<i>Diffusion-weighted imaging</i>
<i>EC</i>	<i>Embryonal carcinoma</i>
<i>FIGO</i>	<i>Federation of Obstetrics and Gynecology</i>
<i>GCTs</i>	<i>Germ cell tumors</i>
<i>Hz</i>	<i>Hertz</i>
<i>ISIS</i>	<i>Image Selected In Vivo Spectroscopy</i>
<i>MCTs</i>	<i>Mature cystic teratomas</i>
<i>MR</i>	<i>Magnetic resonance</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>MRS</i>	<i>Magnetic resonance spectroscopy</i>
<i>NAA</i>	<i>N-acetyl aspartate</i>
<i>OGCTs</i>	<i>Ovarian germ cell tumors</i>
<i>OSE</i>	<i>Ovarian surface epithelial</i>
<i>PRESS</i>	<i>Point Resolved Spectroscopy</i>
<i>RF</i>	<i>Radiofrequencies</i>
<i>ROI</i>	<i>Regions of interest</i>
<i>S/N</i>	<i>Signal to noise ratio</i>
<i>SI</i>	<i>Spectroscopic imaging</i>
<i>STEAM</i>	<i>Stimulated Echo Acquisition Mode</i>
<i>SV</i>	<i>Single-voxel</i>
<i>TOA</i>	<i>Tubo-ovarian abscesses</i>
<i>WHO</i>	<i>World health organization</i>
<i>YST</i>	<i>Yolk sac tumors</i>

List of Tables

Table No.	Title	Page No.
Table (1):	WHO, classification for sex cord tumors	34
Table (2):	TNM staging system for ovarian tumors	45
Table (3):	FIGO Staging of Ovarian Cancer	46
Table (4):	Technical challenges of MRS and possible solutions.....	62
Table (5):	Criteria for differentiating benign from malignant ovarian masses	69
Table (6):	Parameters of pelvic conventional MRI	94
Table (7):	Age distribution in the studied patients.	100
Table (8):	Tumor type stratified by patients' age categories.....	101
Table (9):	CA125 measurement in different tumor types.	102
Table (10):	Histopathological results of the masses in the current study.....	103
Table (11):	Masses diagnosed during follow up.....	103
Table (12):	Lesion signal intensity in conventional MRI (T2).	104
Table (13):	T2 of the studied masses diagnosed during follow up.	105
Table (14):	Choline Peak of the studied masses.....	107
Table (15):	Choline Peak of the studied masses diagnosed during follow up.	108
Table (16):	Area under the curve displaying diagnostic accuracy of Choline for differentiating between benign and malignant tumors.....	109
Table (17):	Best cut off point of Choline Ratio for differentiating between benign and malignant tumors.....	110
Table (18):	Creatine Peak of the studied masses.....	111
Table (19):	Creatine Peak of the studied masses diagnosed during follow up.	112

List of Tables Cont...

Table No.	Title	Page No.
Table (20):	Area under the curve displaying diagnostic accuracy of Creatine for differentiating between benign and malignant tumors.....	113
Table (21):	Best cut off point of Creatine for differentiating between benign and malignant tumors.....	114
Table (22):	Lipid Peak of the studied masses.	116
Table (23):	Lipid Peak of the studied masses diagnosed during follow up.....	117
Table (24):	Naa Peak of the studied masses.	118
Table (25):	Naa Peak of the studied masses diagnosed during follow up.....	119
Table (26):	Cho/Cr Ratio.	120
Table (27):	Area under the curve displaying diagnostic accuracy of Choline/Creatine Ratio for differentiating between benign and malignant tumors.....	122
Table (28):	Best cut off point of Choline/Creatine Ratio for differentiating between benign and malignant tumors.....	123
Table (29):	Correlation between CA125 & Choline/Creatine Ratio.....	124

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Location, the broad ligament (left), and blood supply to the uterus and ovaries (right).....	17
Fig. (2):	Blood Supply to the Female Reproductive Tract	20
Fig. (3):	Sagittal MRI Planes Landmarks.T2 WI	21
Fig. (4):	Axial MRI plane Landmark	23
Fig. (5):	Classification of ovarian tumors	27
Fig. (6):	Unilocular serous cystadenoma. Unilocular ovarian cyst with a thin regular wall.....	29
Fig. (7):	Gross specimen of resected ovarian mucinous cystadenoma	30
Fig. (8):	Gross specimen of resected ovarian endometrioid tumor.....	31
Fig. (9):	Malignant brunner tumor	32
Fig. (10):	Fibroma.....	35
Fig. (11):	Ovarian thecoma.....	36
Fig. (12):	Granulosa cell tumor adult type	37
Fig. (13):	Gross specimen of sertoli leydig tumor.....	38
Fig. (14):	Gross specimen of a large adenexal mass representing a large ovarian teratoma with intralesional hair within.....	40
Fig. (15):	Macroscopic specimen of ovarian yolk sac tumor.....	42
Fig. (16):	Macroscopic specimen of ovarian choriocarcinoma	43
Fig. (17):	Spectra of normal ovarian surface epithelial (OSE) cells, analysis of signal that is detected in an MR study.....	51
Fig. (18):	This example illustrates that the S/N of a spectrum needs to be considered before drawing any conclusions	59
Fig. (19):	Proton MRS in a case of clear cell carcinoma	63

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (20):	Proton MRS in a case of thecoma	64
Fig. (21):	Borderline malignant mucinous cystic tumor in a 29-year-old woman	65
Fig. (22):	Sagittal T2-weighted image with fat saturation shows slightly hyperintense solid mass	66
Fig. (23):	Typical dermoid in a 78-year-old female	68
Fig. (24):	T1a ovarian cancer	70
Fig. (25):	T1b ovarian cancer	70
Fig. (26):	Proton MRS of a case of simple serous cyst revealed Cho, NAA and lactate peaks	73
Fig. (27):	Proton MRS in a case of clear cell carcinoma	74
Fig. (28):	Proton MRS in a case of dysgerminoma	74
Fig. (29):	Proton MRS in a case of fibroma	75
Fig. (30):	Proton MRS in cases of malignant and benign ovarian tumor	77
Fig. (31):	53-year-old women with serous cystadenoma	78
Fig. (32):	27-year-old women with borderline mucinous tumor	78
Fig. (33):	69-year-old women with serous cystadenocarcinoma	79
Fig. (34):	Mucinous cystadenocarcinoma in a 61-year old woman	80
Fig. (35):	Serous cystadenocarcinoma	81
Fig. (36):	Mucinous cystadenocarcinoma in a 61-year old woman	82
Fig. (37):	Mucinous cystadenoma in a 28-year-old woman	82
Fig. (38):	Proton MRS in a case of endometrial cyst	83
Fig. (39):	Proton MRS without water suppression in a case of dermoid cyst	83

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (40):	Proton MRS in a case of mature cystic teratoma	84
Fig. (41):	78-year-old woman with left ovarian mucinous cystadenoma	85
Fig. (42):	44-year-old women with metastatic squamous cell carcinoma	86
Fig. (43):	48-year-old woman with Tuboovarian abscess and pelvic inflammatory disease.....	87
Fig. (44):	47-year-old woman with salpingitis	88
Fig. (45):	37-year-old women with paratubal cyst	88
Fig. (46):	48-year-old women with follicular cyst.....	89
Fig. (47):	38-year-old woman with endometriosis.....	90
Fig. (48):	MRS of cystic ovarian lesions	91
Fig. (49):	Age distribution in the studied patients.	100
Fig. (50):	Tumor type stratified by patients' age categories.....	101
Fig. (51):	CA125 measurement in different tumor types.....	102
Fig. (52):	ROC Curve displaying diagnostic accuracy of Choline for differentiating between benign and malignant tumors	108
Fig. (53):	ROC Curve displaying diagnostic accuracy of Creatine for differentiating between benign and malignant tumors	112
Fig. (54):	ROC Curve displaying diagnostic accuracy of Choline/Creatine Ratio for differentiating between benign and malignant tumors.....	121
Fig. (55):	Correlation between CA125 & Choline/Creatine Ratio.....	124

INTRODUCTION

Ovarian masses account for most common indication for gynecological surgery, but definitive diagnosis is not possible until the surgery and histopathological examination have been performed. However, the preoperative characterization of the lesion is crucial to decide the type of surgery and feasibility of conservative management and probability of malignancy, which is based mostly on imaging appearance (*Sampathi and Sindhu, 2017*).

The optimal assessment of an adnexal mass requires a multidisciplinary approach, based on physical examination, laboratory tests and imaging techniques. An important issue to consider in the management of ovarian masses is that they are very common, but most of them are benign and only a small part is borderline or malignant. Preoperative biopsy should not be performed in ovarian masses, particularly if the mass appears to be surgically resectable at the moment, as this invasive procedure raises the risk of spreading cancer cells and potentially leads to iatrogenic upstaging worsening the prognosis. So diagnostic imaging plays a crucial role in detection, characterization and staging of adnexal masses (*Foti et al., 2016*). However, the only definitive diagnosis of an ovarian masses is through histology (*Yeoh, 2015*).

Several imaging modalities are available for detecting ovarian tumors; however there is no single reliable diagnostic

method. Ultrasonography plays a pivotal role in detecting ovarian lesions and differentiates solid, cystic and complex cystic lesions

With its multiplanar capability, superior tissue contrast and different sequences, MRI becomes a crucial method of investigation of ovarian lesions. MRI has high sensitivity (97%) and specificity (84%) (***Mohaghegh and Rockall, 2012***).

Magnetic resonance (MR) imaging may provide useful information for the characterization of ovarian masses as non-neoplastic or neoplastic, and, in the latter case, as benign or malignant (***Sampathi and Sindhu, 2017***).

Therefore, radiologists play an important role in the multidisciplinary approach of ovarian mass, and, though different pathological conditions may have similar radiologic manifestations, they should be aware of MR imaging features of ovarian lesions that may orientate the differential diagnosis (***Foti et al., 2016***).

Magnetic resonance imaging, MRI, provides high spatial resolution, such that morphology is very well visualized. With the aid of magnetic resonance imaging (MRI), adnexal masses with morphological characteristic that are indeterminate on trans vaginal ultra sound can sometimes be better identified as benign or malignant, and with magnetic resonance spectroscopy it become possible to go beyond anatomy to

assess the metabolic features of tissues or organs (*Belkić and Belkić, 2017*).

MRS is a non-invasive technique that enables the detection, identification, and quantification of biochemical compounds or metabolites in the tissues. Metabolites that can be measured using ¹H-MRS include N-acetyl aspartate (NAA), choline (Cho), creatine (Cr), lactate, glutamine, glutamate, lipids, and macromolecules (*Sidek et al., 2016*).

MRS patterns of benign and malignant adnexal tumors differ. The choline-to-creatine ratio can help clinicians differentiate benign from malignant tumors with 94.1% sensitivity, and 97.1% specificity (*Ma et al., 2015*).

AIM OF THE WORK

The aim of our study is to highlight the role of magnetic resonance spectroscopy as a non-invasive technique which may effectively assist in differentiating benign from malignant ovarian masses.